Literature DB >> 12679928

Expression of growth hormone receptor and its mRNA in hepatic cirrhosis.

Hong-Tao Wang1, Shuang Chen, Jie Wang, Qing-Jia Ou, Chao Liu, Shu-Sen Zheng, Mei-Hai Deng, Xiao-Ping Liu.   

Abstract

AIM: To investigate the expression of growth hormone receptor (GHR) and mRNA of GHR in cirrhotic livers of rats with the intension to find the basis for application of recombinant human growth hormone (rhGH) to patients with liver cirrhosis.
METHODS: Hepatic cirrhosis was induced in Sprague-Dawley rats by administration of thioacetamide intraperitoneally for 9-12 weeks. Collagenase IV was perfused in situ for isolation of hepatocytes. The expression of GHR and its mRNA in cirrhotic livers was studied with radio-ligand binding assay, RT-PCR and digital image analysis.
RESULTS: One class of specific growth hormone-binding site, GHR, was detected in hepatocytes and hepatic tissue of cirrhotic livers. The binding capacity of GHR (R(T), fmol/mg protein) in rat cirrhotic liver tissue (30.8+/-1.9) was significantly lower than that in normal control (74.9+/-3.9) at the time point of the ninth week after initiation of induction of cirrhosis (n=10, P<0.05), and it decreased gradually along with the accumulation of collagen in the process of formation and development of liver cirrhosis (P<0.05). The number of binding sites (X10(4)/cell) of GHR on rat cirrhotic hepatocytes (0.86+/-0.16) was significantly lower than that (1.28+/-0.24) in control (n=10, P<0.05). The binding affinity of GHR among liver tissue, hepatocytes of various groups had no significant difference (P>0.05). The expression of GHR mRNA (riOD, pixel) in rat cirrhotic hepatic tissues (23.3+/-3.1) was also significantly lower than that (29.3+/-3.4) in normal control (n=10, P<0.05).
CONCLUSION: The growth hormone receptor was expressed in a reduced level in liver tissue of cirrhotic rats, and lesser expression of growth hormone receptors was found in a later stage of cirrhosis. The reduced expression of growth hormone receptor was partly due to its decreased expression on cirrhotic hepatocytes and the reduced expression of its mRNA in cirrhotic liver tissue.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679928      PMCID: PMC4611446          DOI: 10.3748/wjg.v9.i4.765

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  57 in total

1.  Improvement of growth after growth hormone treatment in children who undergo liver transplantation.

Authors:  B Rodeck; R Kardorff; M Melter; J H Ehrich
Journal:  J Pediatr Gastroenterol Nutr       Date:  2000-09       Impact factor: 2.839

2.  Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group.

Authors:  M Schambelan; K Mulligan; C Grunfeld; E S Daar; A LaMarca; D P Kotler; J Wang; S A Bozzette; J B Breitmeyer
Journal:  Ann Intern Med       Date:  1996-12-01       Impact factor: 25.391

3.  Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy.

Authors:  D W Hart; D N Herndon; G Klein; S B Lee; M Celis; S Mohan; D L Chinkes; S E Wolf
Journal:  Ann Surg       Date:  2001-06       Impact factor: 12.969

Review 4.  Management of catabolism in metabolically stressed patients: a literature survey about growth hormone application.

Authors:  C A Raguso; L Genton; U Kyle; C Pichard
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2001-07       Impact factor: 4.294

5.  Growth hormone secretagogue binding sites in peripheral human tissues.

Authors:  M Papotti; C Ghè; P Cassoni; F Catapano; R Deghenghi; E Ghigo; G Muccioli
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

6.  The effect of growth hormone on rat pre-antral follicles in vitro.

Authors:  J Zhao; H T van Tol; M A Taverne; G C van der Weijden; M M Bevers; R van den Hurk
Journal:  Zygote       Date:  2000-08       Impact factor: 1.442

7.  The effect of recombinant growth hormone on nitrogen balance in malnourished patients after major abdominal surgery.

Authors:  W K Wong; K C Soo; R Nambiar; Y S Tan; S L Yo; I K Tan
Journal:  Aust N Z J Surg       Date:  1995-02

8.  Hepoxilin A3-specific binding in human neutrophils.

Authors:  D Reynaud; P Demin; C R Pace-Asciak
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

9.  Thioacetamide- and carbon tetrachloride-induced liver cirrhosis.

Authors:  H Dashti; B Jeppsson; I Hägerstrand; B Hultberg; U Srinivas; M Abdulla; S Bengmark
Journal:  Eur Surg Res       Date:  1989       Impact factor: 1.745

10.  Cirrhotic liver expresses low levels of the full-length and truncated growth hormone receptors.

Authors:  X Y Shen; R I Holt; J P Miell; S Justice; B Portmann; M C Postel-Vinay; R J Ross
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

View more
  3 in total

1.  Expression of PCNA and CD44mRNA in colorectal cancer with venous invasion and its relationship to liver metastasis.

Authors:  Shu-Qiang Yue; Yan-Ling Yang; Ke-Feng Dou; Kai-Zong Li
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

Review 2.  Endocrine and liver interaction: the role of endocrine pathways in NASH.

Authors:  Paola Loria; Lucia Carulli; Marco Bertolotti; Amedeo Lonardo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-04       Impact factor: 46.802

3.  Regenerative and fibrotic pathways in canine hepatic portosystemic shunt and portal vein hypoplasia, new models for clinical hepatocyte growth factor treatment.

Authors:  Bart Spee; Louis C Penning; Ted S G A M van den Ingh; Brigitte Arends; Jooske Ijzer; Frederik J van Sluijs; Jan Rothuizen
Journal:  Comp Hepatol       Date:  2005-12-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.